1. Home
  2. CRBP vs LARK Comparison

CRBP vs LARK Comparison

Compare CRBP & LARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$10.59

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Logo Landmark Bancorp Inc.

LARK

Landmark Bancorp Inc.

HOLD

Current Price

$26.74

Market Cap

147.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBP
LARK
Founded
2009
1885
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
147.4M
147.7M
IPO Year
2014
2001

Fundamental Metrics

Financial Performance
Metric
CRBP
LARK
Price
$10.59
$26.74
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$45.60
N/A
AVG Volume (30 Days)
237.0K
4.1K
Earning Date
05-08-2026
04-29-2026
Dividend Yield
N/A
3.14%
EPS Growth
N/A
35.84
EPS
N/A
3.07
Revenue
$4,822,272.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$116.00
N/A
P/E Ratio
N/A
$8.71
Revenue Growth
97.62
N/A
52 Week Low
$6.10
$23.43
52 Week High
$20.56
$31.00

Technical Indicators

Market Signals
Indicator
CRBP
LARK
Relative Strength Index (RSI) 59.58 54.87
Support Level $7.91 $25.40
Resistance Level $10.62 $27.06
Average True Range (ATR) 0.66 0.58
MACD 0.03 0.14
Stochastic Oscillator 63.67 73.23

Price Performance

Historical Comparison
CRBP
LARK

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About LARK Landmark Bancorp Inc.

Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.

Share on Social Networks: